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http://dx.doi.org/10.1016/j.jfma.201
0929-6646/Copyright ª 2015, ElsevierHepatitis E virus (HEV) is the most common cause of acute viral hepatitis worldwide. Originally
considered to be restricted to humans, it is now clear that HEV and HEV-like viruses have
several animal reservoirs with complex ecology and genetic diversity, as exemplified by the
recent discovery of HEV in dromedaries, a previously underestimated reservoir of zoonotic vi-
ruses prior to the emergence of Middle East Respiratory Syndrome coronavirus. Zoonotic food-
borne transmission from pigs and feral animals such as wild boar is of increasing importance in
the rapidly industrializing countries of the Asia Pacific region. Such zoonotic hepatitis E infec-
tion has particular relevance to the increasing population living with immunosuppression, due
to the risk of chronic hepatitis E in these patients. Fortunately, major strides have been made
recently in the management of chronic hepatitis E patients. Furthermore, an effective vaccine
is also available that promises better control of hepatitis E burden in the near future. This re-
view highlights these major recent developments in the epidemiology, treatment, and preven-
tion of hepatitis E.
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Hepatitis E virus (HEV) is a member of the genus Hepevirus
within the family Hepeviridae. It is a nonenveloped virus
measuring approximately 27e34 nm in diameter. The single
stranded, positive sense RNA genome of HEV comprises
three open reading frames (ORFs). ORF1 encodes
nonstructural proteins including methyltransferase,Association. All rights reserved.
682 S. Sridhar et al.protease, helicase, and RNA-dependent RNA polymerase.
ORF2 encodes the capsid protein, which enables virus cell
entry and contains the targets for neutralizing antibodies.
ORF3 encodes a phosphorylated protein that is important
for virus release.1
It is estimated that there are 20 million hepatitis E in-
fections worldwide every year, making it the most common
cause of acute viral hepatitis in most regions including Hong
Kong.2,3 HEV infection is silent in most individuals and when
symptomatic, usually produces a self-limiting icteric
illness. However, progression to severe fulminant liver
failure may occur in certain high-risk groups, such as
pregnant women and elderly patients with underlying liver
disease. Although there is only one serotype, four major
HEV genotypes capable of infecting humans are currently
recognized. HEV genotypes 1 and 2 are only found in
humans and account for most of the hepatitis E in the
developing world where transmission occurs by the fecal-
oral route via contaminated waterways. HEV genotypes 3
and 4 are found in swine and other animals across the
world, sporadically infecting humans in industrialized
countries via foodborne routes. Human-to-human spread in
developed countries is limited to blood-borne transmission
via blood products derived from viremic donors. In addition
to these genotypes of clinical importance, several novel
HEV-like viruses have been discovered in a variety of animal
specimens, similar to each other in overall genomic orga-
nization but differing in terms of the total genome length
and position of ORF3 with respect to the ORF1/2 junction.4Expanding range of animal reservoirs of HEV:
More than just pigs
Domestic pigs are the most important reservoirs of the HEV
genotypes that are capable of infecting humans. HEV3 was
first isolated from swine specimens in the United States in
1997, when it was also discovered that large proportions of
herds across the North American Midwest were seropositive
against HEV, a finding echoed by studies on swine pop-
ulations across the world.5,6 Another genotype of clinical
importance, HEV4, was identified from pigs in Taiwan.7 ThisTable 1 Distribution, hosts, and transmission routes of major h
HEV genotype Natural host Geographical dis
Genotype 1 Humans Asia, Africa
Genotype 2 Humans Africa, Mexico
Genotype 3 Humans, domestic pigs,
wild boar, mongoose, deer
Worldwide distrib
human infection
North/South Ame
and Australia
Genotype 4 Humans, domestic pigs,
wild boar
China, Japan
Rabbit HEV Rabbits China, North Am
Rat HEV Rats Asia, Europe, No
Camel HEV Camels Middle East
Avian HEV Chickens, turkeys Worldwide
a Not applicable as zoonotic potential unknown.genotype has subsequently been found to be enzootic in
China and Japan; it has also recently been reported in
swine populations and autochthonous human infections in
Europe.8e11 HEV infection generally affects young pigs and
is subclinical. Given the high fecal viral loads and prolonged
periods of virus shedding in stool, transmission between
pigs is likely to be fecal-oral.12
HEV genotypes 3 and 4 have also been found in a number
of other animal species, most significantly in animals hun-
ted for game meat such as deer and wild boar.13e15 Closely
related strains have also been detected in mongooses,
rabbits, and rats.16e22 In addition, the discovery of a
number of novel HEV-like viruses from an increasing variety
of animals has brought light to the immense ecological di-
versity of HEVs and has resulted in a call for an expansion
and reorganization of the current classification system of
the Hepeviridae family.23e38 As an example, our recent
work on dromedary camels has not only led to the discovery
of a novel genotype of HEV, but is also the first description
of different genomic features in different strains of the
same HEV.38 The geographical distribution of terrestrial
animal reservoirs of HEV is summarized in (Table 1) and
(Fig. 1).Accumulating evidence for zoonotic
transmission to humans
Zoonotic transmission of HEV3 and HEV4 to humans is well
established by various lines of evidence. Increased HEV
seroprevalence in swine handlers compared to the general
public provides indirect evidence for subclinical infection
due to contact with infected animals.39,40 Nonhuman pri-
mates have been successfully infected by both HEV geno-
types 3 and 4 in experimental settings, proving the
feasibility of zoonotic infection.3,41 Epidemiological studies
from outbreaks and case series show that a history of
consumption of uncooked deer, wild boar meat, and shell-
fish is a risk factor for acquiring hepatitis E.42e44 The
foodborne zoonotic source hypothesis is further supported
by the high sequence similarity of HEV gene sequences from
patients with autochthonous hepatitis E and animal sourcesepatitis E virus (HEV) genotypes.
tribution Transmission route in human infection
Human-to-human, waterborne outbreaks
Human-to-human, waterborne outbreaks
ution in pigs,
in Europe,
rica, East Asia,
Zoonotic foodborne, blood products
Zoonotic foodborne
erica, Europe Some evidence for zoonotic transmission,
pending definitive confirmation
rth America N/Aa
N/Aa
N/Aa
Figure 1 Geographical distribution of hepatitis E virus 3 (HEV3), HEV4, and novel HEV-like viruses in terrestrial animals. Pigs, wild
boar, and deer have been definitively implicated in zoonotic transmission of HEV3 and HEV4 to humans. The role of mongooses,
rats, and rabbits in causing human hepatitis E is unclear.
Recent developments in hepatitis E 683in the same region.45,46 HEV3 and HEV4 RNA are frequently
detected in meat products originating from pigs and feral
animals that are sold for human consumption.45e49 In a
local study in Hong Kong, 31% of pig liver samples were
positive for HEV RNA and the sequences were identical to
human cases in the region, highlighting the risk of acquiring
hepatitis E from consumption of foods such as pig liver
congee, which is a common delicacy in the region.50 Ho-
mogenates of such contaminated meat have been suc-
cessfully used to infect pigs, demonstrating that the HEV
RNA forms a part of the fully viable infectious particles.49
Deserving special mention is the recent detection of HEV3
RNA from shellfish, which may be an emerging, indirect
vehicle for zoonotic transmission and highlights the health
risks of consuming undercooked bivalves that filter feed in
waterbeds supplied by runoff contaminated with swine
excreta or viscera.51 Due to rapid industrialization and
improvement in sanitary conditions in many parts of East
Asia, zoonotic HEV transmission is assuming an increasing
importance with a resultant genotype switch from HEV1 to
HEV3 or HEV4.8 In other developing countries in Asia,
although HEV genotypes are frequently detected in pigs and
other animals, most human disease still occurs by per-
soneperson spread of HEV1.52 However, even in such set-
tings, zoonotic transmission may account for some hepatitis
E cases.53 Although rat, rabbit, and mongoose populations
are known to harbor HEV strains that are closely related to
human pathogenic HEV strains, their role in causingzoonotic human hepatitis E is unclear at this stage.16e22 The
potential of rats to harbor infectious HEV is a particular
concern due to their close proximity to urban human
dwellings. As for the possible role of dromedary camel HEV,
although a study has shown that HEV is the commonest
cause of acute hepatitis in Dubai,54 no sequence informa-
tion from the HEV strains involved is available. Further
genomic studies on HEV from Dubai patients should reveal
the importance of dromedaries as the possible source of
HEV in the Middle East.Clinical significance of animal HEV reservoirs
The ubiquitous presence of HEV3 and HEV4 in various ani-
mal reservoirs has a direct impact on clinical practice.
Patients presenting with acute hepatitis should be asked
about recent consumption of undercooked pork, shellfish,
or game meat. Contact with swine or their effluent should
be explored. Transfusion of blood products is also a po-
tential route of acquisition of hepatitis E. Patients report-
ing such exposures should be tested for HEV
immunoglobulin M or RNA. Besides expediting diagnosis,
such epidemiological clues could also enable treatment of
certain groups of patients at risk of chronic hepatitis E
infection (see below) and facilitate outbreak investigation.
Although most zoonotic HEV cases are sporadic, point
source foodborne HEV outbreaks are well documented.44
684 S. Sridhar et al.Acquisition of HEV through the use of porcine derived
medical products such as heparin, insulin, or coagulation
factors has never been convincingly demonstrated, but
remains a theoretical possibility given the ubiquity of HEV
in swine populations.55
The zoonotic potential of the increasing number of
newly discovered HEV genotypes is unclear at this stage.
These viruses demonstrate high host specificity: interspe-
cies transmission of non-3, non-4 HEVs is seldom achieved
in experimental infection settings and also appears to be
rare in nature.3,56 However, this possibility should always
be considered in patients presenting with acute hepatitis
after contact with exotic animals or consumption of their
meat. If the novel HEV has highly divergent nucleotide se-
quences, the performance of conventional serological
diagnostic tests is uncertain. However, the use of pan-
hepeviral consensus primers will still enable such cases to
be recognized. The increasing use of unbiased next gener-
ation sequencing on randomly amplified nucleic acid ex-
tracts as part of metagenomic analysis of patient specimens
may also enable detection of novel HEVs in clinical settings.
The understanding of reservoirs and routes of trans-
mission enables the institution of specific preventive mea-
sures. Public health education on the avoidance of
undercooked meat and seafood remains the single most
important preventative measure; there is evidence to sug-
gest that boiling meat or stir-frying at high heat for 5 mi-
nutes can inactivate infectious viral particles.57 Patients
who face immunosuppression should be reminded of such
dietary practice given the potentially severe sequelae of
hepatitis E in this group. Vaccination is an attractive
alternative, but its cost-effectiveness for population-wide
usage remains to be evaluated. HEV control at the level
of animal husbandry remains to be assessed; measures such
as housing swine in barrier conditions and regular screening
of HEV RNA have been proposed for herds raised to provide
xenotransplants and other medical products.58 However,
such methods are likely to be inhumane and commercially
impractical for swine raised for the food industry. With
increasing public recognition of the risk of foodborne hep-
atitis E, HEV control solutions at other steps in the meat
production chain must be sought.HEV infection in immunocompromised patients
Hepatitis E was previously considered to be a cause of acute
hepatitis with no progression to chronic carriage. However,
this perception changed with the publication of a case se-
ries of 14 solid organ transplant recipients with acute
autochthonous HEV3 infection in southern France.59 The
authors showed that eight of the 14 patients progressed to
chronic hepatitis characterized by mild derangement in
liver enzymes, persistently detectable HEV RNA in serum
and stool for > 3 months, delayed/absent HEV serocon-
version, and histological features of chronic viral hepatitis
such as dense lymphocytic periportal infiltrates with
piecemeal necrosis. Chronic HEV carriage has been
described in liver, kidney, pancreas, heart-lung, and stem
cell transplant recipients.59e64 Autochthonous hepatitis E
infection in the posttransplant setting appears to be un-
common. Screening studies of HEV RNA in the sera of livertransplant recipients showed a hepatitis E infection prev-
alence of < 1% in Europe.65,66 However, approximately half
of all patients with acute autochthonous hepatitis E in the
posttransplant period progress to chronic infection; con-
version rates of 80% have been reported in one French case
series.58,67 The prevalence of chronic hepatitis E among
transplant recipients in Asian countries is unknown.
Alarmingly, a significant proportion of these chronic HEV
carriers rapidly progress to cirrhosis and portal hyperten-
sion.60 The inability to clear HEV viremia is directly related
to the degree of immunosuppression of these patients at
the time of infection. Therefore, infections that occur
shortly after transplantation, rejection episodes, or when
the patient has low total lymphocyte counts are more likely
to progress to chronic infection.43 The use of tacrolimus (as
opposed to ciclosporin) is also known to be a risk factor for
chronic HEV in posttransplant patients.43 HEV immuno-
globulin G seropositivity prior to transplantation does not
exclude these patients from reinfection post-
transplantation and such reinfections have been reported
to progress to chronic infection.68 Reactivation of endoge-
nous HEV post-stem cell transplantation has also been
reported.69
Chronic HEV infection has also rarely been described in
two other immunocompromised patient groups e HIV car-
riers and patients with hematological malignancy. From the
little data available, it appears that chronic HEV coinfec-
tion in some HIV positive patients with low CD4 counts (<
200 cells/mL) produces severe liver injury with rapid pro-
gression to cirrhosis.70e74 Awareness and recognition of this
entity is crucial as specific therapy is available to halt dis-
ease progression (see below). The exact prevalence of
chronic HEV carriage in the HIV carrying population remains
to be delineated. The description of chronic HEV in patients
with leukemia and lymphoma on chemotherapy is limited to
a few case reports.75e77 Although this may reflect that the
condition is uncommon, underdiagnosis due to lack of
awareness among clinicians is a possibility.
There are many causes of liver function derangement in
transplant patients including drugs, cytomegalovirus dis-
ease, graft rejection, graft versus host disease, etc. Hep-
atitis E is often not considered in the list of differentials by
physicians. Even when hepatitis E is considered, an inap-
propriate diagnostic strategy may result in the diagnosis
being missed. This is because enzyme immunoassay based
tests that are frequently used for exclusion of acute hep-
atitis E in immunocompetent patients are unreliable for
diagnosis in immunocompromised patients, due to their
variable timeframe to seroconversion.57,78 HEV reverse
transcriptase-polymerase chain reaction of blood and stool
specimens should be considered in any immunocompro-
mised patient with deranged liver function tests of un-
known etiology. Although only three groups of
immunocompromised patients have been identified to be at
risk for chronic hepatitis E so far, clinicians may also face
this condition in other patients with profound chronic
immunosuppression e especially autoimmune conditions
such as systemic lupus erythematosus.
Most cases of chronic HEV infection are related to the
consumption of undercooked pork or, in some cases, mus-
sels and game meat.79 Blood product transfusions are a
potentially important mode of acquisition as well. In the
Recent developments in hepatitis E 685United Kingdom, it has recently been estimated that one in
2848 donors have hepatitis E viremia at the time of dona-
tion.80 This was associated with acute hepatitis as well as
persistent infection in some immunocompromised re-
cipients. This raises questions about the need for screening
blood products for HEV RNA prior to transfusion to groups at
risk of persistent infection. Given the asymptomatic or mild
course of the majority of cases of hepatitis E infection in
the general population, instituting generalized screening of
blood products for HEV prior to transfusion requires a
thorough cost-effectiveness analysis. Transmission of HEV
via an infected liver graft has been reported.81
Most cases of chronic HEV are reported from Europe and
the Americas. Unsurprisingly, nearly all the HEV isolates
from these patients belong to genotype 3, the predom-
inating HEV genotype in these areas. The first case of HEV4
chronic infection has only recently been described in a
patient from China.77 The potential of HEV1 and HEV2 to
establish chronic infection in human beings is unknown.
With wider availability of molecular diagnosis and
sequencing, close surveillance of transplant recipients and
HIV positive patients in developing countries should be
undertaken to define this risk.
A comparative summary of clinical features and diag-
nosis of acute and chronic forms of hepatitis E is presented
in (Table 2).Treatment of HEV infections
Immunocompromised patients diagnosed with hepatitis E
should be closely followed up with regular monitoring of
blood HEV RNA viral load, liver function tests, and liver
stiffness. Delay in the management of persistent viremia
should be minimized due to the potentially rapid onset of
irreversible liver injury. Reduction in immunosuppression
should be considered for patients with persistent HEV
viremia for > 3 months. If viremia still persists or if
immunosuppression is otherwise essential, specific antiviral
treatment or immunomodulation should be considered.
Immunomodulation with pegylated interferon has been
used successfully in liver transplant recipients with chronic
hepatitis E, but its wider use in the transplant setting is
discouraged due to the risk of graft rejection.82 A 24-weekTable 2 Clinical spectrum and management of hepatitis E.
Acute hepatitis E
Risk factors e Travel to HEV endemic areas
e Consumption of undercooked pork, deer, wild
bivalves
e Recently received blood products
e Severe disease in pregnancy, elderly, and patie
with underlying liver disease
Clinical
features
Icteric illness, usually self-limiting, but may prog
to fulminant hepatitis in high-risk patients
Diagnosis HEV IgM, may consider HEV RT-PCR of stool/plasm
for diagnosis/genotyping
Treatment Supportive
HEV Z hepatitis E virus; IgM Z immunoglobulin M; RT-PCR Z reversecourse of pegylated interferon has been used to treat HIV
positive patients with chronic HEV.72
There is accumulating evidence for the use of the gua-
nosine analogue ribavirin in persistently viremic patients
who fail a trial of immunosuppression reduction.83e85 In a
recent case series involving 59 post-solid organ transplant
patients with chronic hepatitis E, ribavirin monotherapy for
a median of 3 months resulted in a sustained virological
response (defined in the study as clearance of viremia for
25 months after treatment) in 78% of patients.85 Liver
function tests normalized in all of these patients. Some
patients who developed recurrent viremia achieved sus-
tained virological response after retreatment with ribavirin
for 6 months. Anemia was the most important treatment
related side effect. Six months of ribavirin monotherapy
has also been used anecdotally in HIV patients with chronic
HEV with clearance of viremia and improvement in liver
stiffness and liver function tests.74 The effect of antire-
troviral therapy in facilitating clearance of HEV viremia is
unknown.
Patients with delayed diagnosis who present with liver
cirrhosis may be considered for liver transplantation.
However, reactivation of HEV after liver transplantation for
chronic hepatitis E has been described; this can result in
recurrent hepatitis of the liver graft.69 Therefore, virolog-
ical clearance with ribavirin should be considered before
considering transplantation for this patient group. The
management of immunocompromised patients diagnosed
with hepatitis E is summarized in (Fig. 2).
Ribavirin has anecdotally been used for treatment of
acute hepatitis E in both immunocompetent and HIV posi-
tive patients.86e89 It is unclear whether the patients
recovered due to ribavirin use or as a result of the natural
course of the disease. It is generally accepted that the
acute hepatitis following HEV infection arises from immu-
nopathology rather than a direct viral cytopathic effect.
Therefore, the biological role of ribavirin in modulating
disease progress is unclear. Controlled trials are required to
define the role of ribavirin in the treatment of patients with
acute hepatitis E. Ribavirin prophylaxis has been described
for postexposure prophylaxis of some viral hemorrhagic
fever viruses.90 This raises the intriguing possibility of
ribavirin for postexposure prophylaxis in sequestered
outbreak settings, such as refugee camps and militaryChronic hepatitis E
boar,
nts
Patients with acute hepatitis E who are:
e Solid organ or hemopoietic stem cell transplant
recipients
e Receiving chemotherapy for hematological
malignancy
e HIV positive with CD4 counts <200/mL
ress Acute phase often asymptomatic, progression to
cirrhosis and portal hypertension over months-years
a HEV RT-PCR of stool/plasma, serology is not reliable
Refer to Fig. 2 for treatment algorithm
transcriptase-polymerase chain reaction.
Figure 2 Management overview of hepatitis E in immunocompromised patients. a In HIV positive patients, may alternatively
consider 6 month course of pegylated interferon therapy  ribavirin. b Evidence based on 1 case series and several case
reports.83e85 c Evidence based on 1 case series.85 HEV Z hepatitis E virus; RT-PCR Z reverse transcriptase-polymerase chain
reaction.
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Recent developments in hepatitis E 687encampments, to suppress initial viral replication. Howev-
er, ribavirin is strictly contraindicated in pregnant women,
limiting its use in an important high-risk group. Therefore,
hepatitis E vaccination still remains the most important
prospect for disease prevention in such settings (see
below).Hepatitis E vaccination
HEV 239 (Hecolin), a recombinant bacterially expressed
polypeptide vaccine based on a 26 kDa segment of HEV
genotype 1 ORF2, was licensed in China in 2011. The poly-
peptide takes the form of a virus-like particle with surface
presentation of immunodominant epitopes for optimal
immunogenicity.91e93 In a Phase III clinical trial involving
112,604 participants from 11 townships in China, healthy
adults were randomized to receive either three doses of
HEV 239 (at 0 months, 1 month, and 6 months) or placebo
(hepatitis B vaccine).94 They were followed up for 13
months after receiving the third dose. No participants in
the HEV 239 vaccine arm, who had received at least two
doses, developed clinical hepatitis E during the follow up
period. Vaccine efficacy at 19 months after one dose of HEV
239 was estimated to be 95.5% (95% Confidence Interval
66.3e99.4). In a subsequent analysis on the vaccinated
population, protection extends to 2 years after vaccination
and is independent of hepatitis B carrier status.95,96 The
vaccine was well tolerated and also appears to be safe in
pregnancy on preliminary analysis.97 Interestingly, the
majority of patients in the placebo group who developed
clinical hepatitis E had genotype 4 HEV RNA on sequencing.
This supports previous animal studies that found this ge-
notype 1 based vaccine to be highly cross protective against
HEV4, a zoonotic genotype. This is a significant finding that
encourages trial of the vaccine in areas with HEV3 pre-
dominance. While the vaccine appears highly promising,
questions remain about the duration of protection, efficacy
in outbreak settings, immunogenicity in young children,
immunogenicity against HEV3, and efficacy in immuno-
compromised patients. A Phase IV trial, currently in prog-
ress, involving individuals above the age of 65 years, will
address the effectiveness of the vaccine in elderly re-
cipients, a group at risk for severe zoonotic HEV infection.98
The HEV 239 vaccine has also been shown to be highly
immunogenic in rabbits, conferring protection against both
HEV4 and rabbit HEV.99 If vaccination is found to be
effective in blocking transmission in swine populations,
animal vaccination may be an effective intervention to
reduce zoonotic hepatitis E in developed countries.
The rHEV vaccine is another capsid antigen based puri-
fied polypeptide vaccine produced in insect cell lines
infected by a recombinant baculovirus vector. This vaccine
was found to be safe and effective in a Phase II trial
involving HEV seronegative army recruits in Nepal, where
HEV1 predominates. Further assessment of this vaccine is
pending.100
In the light of the above evidence, the HEV 239 vaccine
may be offered to healthy adults at risk of acquiring hep-
atitis E  a population that includes residents and travelers
to HEV1 and HEV4 endemic areas. Vaccine efficacy in
outbreak settings, HEV3 endemic areas, pediatricpopulations, and immunocompromised patients require
further study.
Conclusion: New answers, new questions
With a better understanding of HEV come new challenges.
While improvement of sanitation facilities is the clear (if
difficult to achieve) solution for hepatitis E control in
resource-poor settings, the roadmap for autochthonous
foodborne disease control in developed countries is less
clear. Effective HEV control in meat production chains will
take a major industry initiative, but may be the only way
forward for sustained control of autochthonous hepatitis E.
The need to screen blood products for HEV RNA is currently
under debate and is generating considerable public interest.
Further refinement of treatment paradigms of acute and
chronic hepatitis E is required. The genetic basis for reduced
viral ribavirin susceptibility should be defined for patients
who fail ribavirin therapy. Alternatives such as favipiravir
should be explored in case of ribavirin treatment failure in
chronic hepatitis E patients. Finally, political will and
resourcemobilization is required to export the effective and
safe vaccine to areas where it is most required. Ongoing
characterization of novel animal HEV genotypes is important
due to the possibility of such viruses undertaking a species
jump to cause human infections in the future.
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